Ignite Creation Date:
2025-12-25 @ 2:46 AM
Ignite Modification Date:
2026-03-22 @ 9:03 AM
Study NCT ID:
NCT04620733
Status:
COMPLETED
Last Update Posted:
2024-09-05
First Post:
2020-11-04
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Sponsor:
Gilead Sciences
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CB8025-32048
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None